Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686).

doi:10.1158/1078-0432.CCR-15-1260

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686).

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 May 2016

Karlovich Chris, Goldman Jonathan W, Sun Jong-Mu, Mann Elaina, Sequist Lecia V, Konopa Krzysztof, Wen Wei, Angenendt Philipp, Horn Leora, Spigel David, Soria Jean-Charles, Solomon Benjamin, Camidge D Ross, Gadgeel Shirish, Paweletz Cloud, Wu Lin, Chien Sean, O'Donnell Patrick, Matheny Shannon, Despain Darrin, Rolfe Lindsey, Raponi Mitch, Allen Andrew R, Park Keunchil, Wakelee Heather

Abstract excerpt

PURPOSE: The evaluation of plasma testing for the EGFR resistance mutation T790M in NSCLC patients has not been broadly explored. We investigated the detection of EGFR activating and T790M mutations in matched tumor tissue and plasma, mostly from patients with acquired resistance to first-generation EGFR inhibitors. EXPERIMENTAL DESIGN: Samples were obtained from two studies, an observational study and a phase I...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Clinical Trials, Phase I as Topic

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Observational Studies as Topic

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 26747242
DOI: 10.1158/1078-0432.CCR-15-1260
PMCID: PMC6886231

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686).PMID 26747242Read ↗

Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.Semantic proximity Read ↗

Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial.Semantic proximity Read ↗

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology.Semantic proximity Read ↗

Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions.Semantic proximity Read ↗

Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.Semantic proximity Read ↗

A comparative study of EGFR oncogenic mutations in matching tissue and plasma samples from patients with advanced non-small cell lung carcinoma.Semantic proximity Read ↗

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.Semantic proximity Read ↗

Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.Semantic proximity Read ↗

Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas.Semantic proximity Read ↗

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.